AI-Discovered Lung Disease Drug Rentosertib Exhibits Potential Anti-Aging Effects in Phase 2a Trial

Recent findings published in the journal Nature Biotechnology have introduced a compelling intersection between disease-specific therapeutics and the rapidly expanding field of longevity science. Researchers evaluating blood samples from a Phase 2a clinical trial for rentosertib—an experimental drug engineered by artificial intelligence to treat idiopathic pulmonary fibrosis (IPF)—discovered that the therapy simultaneously lowered biological age metrics across six distinct proteomic clocks. While the results mark a significant milestone in validating the utility of aging biomarkers within traditional clinical settings, scientists emphasize the ongoing challenge of distinguishing a broad systemic deceleration of aging from the targeted therapeutic reversal of fibrotic disease pathways.

Idiopathic pulmonary fibrosis is a severe, progressive, and fundamentally age-related condition characterized by the abnormal accumulation of scar tissue within the lungs, which severely compromises respiratory function. With a typical onset around the age of 65, IPF shares deep mechanistic overlaps with biological aging, notably chronic inflammation and cellular senescence. Rentosertib was developed by longevity biotechnology firm Insilico Medicine utilizing a proprietary, generative AI-driven drug discovery engine. The drug functions as an inhibitor of TNIK (TRAF2- and NCK-interacting kinase), an enzyme heavily implicated in cellular stress responses, metabolic regulation, and fibrogenesis.

The underlying clinical trial evaluated by the researchers was a 12-week, randomized, double-blind, placebo-controlled Phase 2a study originally designed to test the safety, tolerability, and efficacy of rentosertib in IPF patients. Out of 71 total participants enrolled in the initial trial, the biomarker sub-analysis successfully incorporated blood samples from 42 individuals. The study tested a placebo alongside three distinct dosing regimens: 30 milligrams administered once daily, 30 milligrams administered twice daily (split dose), and 60 milligrams administered once daily as a single dose.

To assess whether the therapeutic intervention exerted systemic effects beyond the lungs, the research team employed six advanced proteomic clocks. Unlike traditional epigenetic clocks that rely on DNA methylation patterns, proteomic clocks analyze the complex abundance of circulating proteins in blood plasma. These tools offer distinct advantages in clinical interpretability, allowing researchers to trace precisely which proteins drive specific biological age readings and connect those shifts directly to underlying physiological mechanisms. Among the six clocks utilized—all trained on large-scale population data from the UK Biobank, including one developed internally by Insilico—four were calibrated against chronological age, while two were specifically designed to predict mortality risk.

The analytical outcomes revealed a consistent downward shift in predicted biological age among patients receiving rentosertib, though the magnitude and consistency varied across dosing schedules and specific clock metrics. Following four weeks of treatment, the four chronological age-based clocks indicated that patients in the 60-milligram single-dose group appeared, on average, approximately three years younger than their baseline measurements prior to the intervention. These shifts achieved statistical significance when compared directly against the placebo cohort. Conversely, the two mortality-risk-prediction clocks did not register statistically significant alterations at that specific four-week milestone for the high single-dose group.

Meanwhile, patients managed on the 30-milligram twice-daily split-dose regimen demonstrated the most robust and uniform biological age reductions across both chronological and mortality-based clocks. Notably, the most pronounced decreases in predicted biological age universally manifested by the fourth week of treatment, with minimal incremental changes observed over the subsequent eight weeks of the trial. Investigators are careful to clarify these findings: the data demonstrates that the circulating blood protein profiles of treated patients shifted to closely resemble patterns conventionally associated with younger populations, but it does not conclusively prove that the intervention successfully reversed chronological aging or extended human lifespan.

Beyond the headline-grabbing clock readings, comprehensive proteomic profiling revealed that rentosertib administration altered the circulating concentrations of 326 distinct blood proteins. These proteins spanned functional categories heavily linked to metabolic health, cellular stress adaptation, and tissue remodeling. In the two higher-dose cohorts, the majority of these protein-level changes persisted throughout the duration of the trial or emerged progressively during later weeks, indicating that the pharmacological agent continued to exert active biological influence even after the numerical biological age readings had plateaued.

A critical methodological hurdle in modern geroscience is determining whether changes in biological clocks reflect a holistic rejuvenation of the organism or merely the successful treatment of a localized pathology. When researchers interrogated which specific proteins contributed most heavily to the younger age estimates generated by the six clocks, a prominent fibrosis-associated protein known as LTBP2 emerged as a primary driver. Because LTBP2 factored into the calculations of all six clocks, a vital scientific question arose: do these algorithmic agreements primarily capture the targeted clearance of pulmonary fibrosis rather than a generalized deceleration of the aging process?

To address this confounding variable, the investigative team performed rigorous correlative analyses comparing individual changes in predicted biological age against objective measurements of lung function improvements. The data indicated that shifts in proteomic clocks did not tightly parallel improvements in pulmonary capacity. While lung function metrics do not encapsulate every systemic manifestation of IPF, this decoupling suggests that localized relief from lung scarring alone may not fully account for the broad protein profile transformations observed in the blood.

Further strengthening the case for systemic geroprotection, researchers compared the treatment-induced protein shifts against established molecular differences observed between younger and older cohorts within the UK Biobank database. In patients receiving the split-dose regimen, proteins historically elevated in older adults systematically declined, while proteins more abundant in younger individuals increased. This restorative biographical pattern did not reach statistical significance within the single-daily-dose group. Furthermore, analysis of senescence-associated proteins revealed that while such markers tended to accumulate naturally in the placebo group over the course of the trial, rentosertib administration successfully suppressed their expression, pointing toward a potential senotherapeutic or anti-inflammatory effect.

Vadim Gladyshev, a professor of medicine at Harvard Medical School and a co-author of the study, emphasized the broader methodological implications of the research in a statement to Lifespan News. "This study illustrates how biomarkers of aging can be incorporated into conventional clinical trials," Gladyshev noted. "If validated more broadly, such approaches could allow us to learn not only whether a treatment affects a particular disease, but also whether it influences some aspects of aging biology."

The publication of these findings significantly elevates the scientific discourse surrounding the dual utility of disease-modifying therapies. Because fundamental aging drivers—such as chronic low-grade inflammation, metabolic dysfunction, and cellular senescence—are intimately intertwined with fibrotic and age-related degenerative diseases, separating a drug’s primary therapeutic indication from its secondary geroprotective potential remains a complex endeavor. Nevertheless, the integration of multi-clock proteomic analysis into Phase 2 clinical trials establishes a powerful, repeatable framework for future drug development. As artificial intelligence continues to accelerate the identification of novel therapeutic compounds like rentosertib, the systematic evaluation of human clinical data through the lens of aging biology may soon transition from an exploratory academic pursuit into a standard pillar of modern pharmaceutical validation.